HylCaryo™ is our next-generation hyaluronic acid (HA)-derived nanoparticle (HANP) platform specifically developed for the targeted delivery and controlled release of RNA and nucleic acid therapeutics. Through modular engineering of HA’s molecular weight, degree of substitution, and particle assembly, HylCaryo™ enables precise loading, protection, and release kinetics tailored for various RNA modalities, including siRNA, mRNA, and gene-editing systems.